WHO adds an HPV vaccine for single-dose use
WHO announced that a fourth WHO-prequalified human papillomavirus (HPV) vaccine product, Cecolin® ha
www.who.intHere are the latest developments on the HPV vaccine based on the most recent publicly available reports:
- One-dose HPV vaccine option: The World Health Organization (WHO) approved the use of Cecolin®, a fourth HPV vaccine product, for single-dose schedules in certain contexts. This supports expanded vaccine supply and could help reach more girls with protection against cervical cancer. This is part of ongoing efforts to simplify vaccination logistics and improve coverage, especially in low- and middle-income countries.[1]
- Global impact and funding: Projections from global health partners indicate vaccination scale-up could avert millions of cervical cancer cases and deaths as coverage expands, with new funding commitments from organizations such as the Gates Foundation, UNICEF, and the World Bank contributing to accelerated introductions and higher coverage by 2030.[2]
- Therapeutic vaccine research: WHO has highlighted research into therapeutic (treatment-directed) vaccines for HPV infections as a potential future complement to preventive vaccines, aiming to help those already exposed to HPV reduce risk of progression to cancer. This remains investigational but represents a potential additional tool in cervical cancer elimination efforts.[3]
If you’d like, I can:
- Narrow to news specific to the United States or Texas.
- Pull the latest official statements or press releases from WHO, CDC, or reputable health journals.
- Create a quick summary of what a single-dose rollout could mean for local clinics or school-based vaccination programs.
Would you like me to focus on a particular region or provide a concise, up-to-date news digest with citations?